Sunday, November 22, 2026

NVIDIA Locks In Eli Lilly and Thermo Fisher as BioNeMo Becomes Global Pharma AI Backbone

NVIDIA signed simultaneous AI platform deals with Eli Lilly and Thermo Fisher in January 2026, establishing BioNeMo as the foundational infrastructure layer for pharmaceutical research worldwide. The agreements triggered foundation model launches from at least five specialized biotech firms across Europe and North America. The move mirrors how AWS and Azure captured cloud infrastructure: before application markets matured.

This article was written by AI. Built from the source documents listed below. How we work

Source Trace Score1 source document1 with a live linkVerifiability: Basic
NVIDIA Locks In Eli Lilly and Thermo Fisher as BioNeMo Becomes Global Pharma AI Backbone
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

NVIDIA signed AI platform agreements with Eli Lilly and Thermo Fisher simultaneously in January 2026, positioning BioNeMo as the default infrastructure layer for global pharmaceutical research.1

The deals immediately triggered foundation model launches from five specialized biotech firms: Basecamp Research, Boltz, Owkin, Edison Scientific, and Natera, spanning biodiversity genomics, biomolecular structure prediction, and federated hospital data.1

BioNeMo provides pre-trained biological AI models covering protein structure, molecular generation, and genomics. Drug developers integrate these directly into pipelines rather than building from scratch. The model lowers the barrier for mid-sized biotech firms globally that lack NVIDIA's compute scale or the research headcount of competitors like Google DeepMind in London.

The infrastructure-layer strategy is well-tested. AWS and Azure became the substrate for entire software ecosystems. NVIDIA is replicating that playbook in life sciences: providing the platform, capturing margin, and staying out of direct competition with the applications built on top.

Thermo Fisher's partnership extends BioNeMo's reach into physical laboratory instrumentation across global scientific facilities. That hardware-software integration, connecting AI models to bench-level workflows, is significantly harder to replicate than software-only agreements.

European and North American biotech firms are building on shared infrastructure rather than maintaining proprietary compute. Owkin, based in Paris and New York, specifically targets federated learning across hospital datasets in multiple jurisdictions. Each firm specializes; all increasingly depend on NVIDIA's substrate.

Regulatory frameworks for AI-assisted drug approval remain incomplete across most jurisdictions: the EU AI Act does not yet fully address pharmaceutical applications, and the US FDA is still developing its AI/ML guidance for drug development. The infrastructure layer is consolidating faster than the regulatory layer can follow.

NVIDIA's position has shifted structurally. It is no longer primarily a chip supplier to pharma: it is a platform owner with recurring relationships at the top of the global drug development stack. That is a different and more durable business.1

Source documents

Via News is a conduit. We point to the source documents behind this report: we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· January 12, 2026
    NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Built from 1 source document, dated 12 Jan 2026
  2. Published 1 May 2026
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›

In this story · Knowledge Files

Via News Editorial Team

The Via News Editorial Team writes analysis and news from the Via News source-traceability system, under the editorial responsibility of L. Miguel Salvado, Editor. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. Articles generated with AI say so under the byline, as the EU AI Act requires.